Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/s41598-021-83641-y

http://scihub22266oqcxt.onion/10.1038/s41598-021-83641-y
suck pdf from google scholar
33637783!7910541!33637783
unlimited free pdf from europmc33637783    free
PDF from PMC    free
html from PMC    free
PDF vom PMID33637783 :   free

suck abstract from ncbi

pmid33637783
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations #MMPMID33637783
  • Pawlowski C; Puranik A; Bandi H; Venkatakrishnan AJ; Agarwal V; Kennedy R; O'Horo JC; Gores GJ; Williams AW; Halamka J; Badley AD; Soundararajan V
  • Sci Rep 2021[Feb]; 11 (1): 4741 PMID33637783show ga
  • Clinical studies are ongoing to assess whether existing vaccines may afford protection against SARS-CoV-2 infection through trained immunity. In this exploratory study, we analyze immunization records from 137,037 individuals who received SARS-CoV-2 PCR tests. We find that polio, Haemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), Varicella, pneumococcal conjugate (PCV13), Geriatric Flu, and hepatitis A/hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations. Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI (0.32, 0.64), p-value: 6.9e-05). Overall, this study identifies existing approved vaccines which can be promising candidates for pre-clinical research and Randomized Clinical Trials towards combating COVID-19.
  • |Adolescent[MESH]
  • |Adult[MESH]
  • |Aged[MESH]
  • |COVID-19/epidemiology/*prevention & control[MESH]
  • |Child[MESH]
  • |Child, Preschool[MESH]
  • |Female[MESH]
  • |Haemophilus Vaccines/therapeutic use[MESH]
  • |Humans[MESH]
  • |Immunization[MESH]
  • |Infant[MESH]
  • |Influenza Vaccines/therapeutic use[MESH]
  • |Male[MESH]
  • |Measles-Mumps-Rubella Vaccine/therapeutic use[MESH]
  • |Middle Aged[MESH]
  • |Pneumococcal Vaccines/therapeutic use[MESH]
  • |Poliovirus Vaccines/therapeutic use[MESH]
  • |Protective Factors[MESH]
  • |SARS-CoV-2/isolation & purification[MESH]
  • |Vaccines, Conjugate/therapeutic use[MESH]
  • |Viral Hepatitis Vaccines/therapeutic use[MESH]
  • |Young Adult[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    4741 1.11 2021